Skip navigation

Strategic Forecasting, Accounting Estimates, Analytics and Financial Reporting for Life Science Companies

November 15-16, 2018
  • Philadelphia, PA

The definitive industry GTN event that convenes over 300 Accounting, Finance, Managed Markets and Contract Analytics executives each year!

The materiality and complexity of gross-to-net continues to grow. For life science companies of all sizes and stages, proactive and strategic management of GTN is critical. CBI’s longstanding Gross-to-Net Summit is built for the learning needs and changing dynamics of pharmaceutical, biotech and generic drug companies. Whether your organization is pre-commercial revenue or is managing multiple products and large revenue streams, an understanding of GTN models and processes is paramount to success and compliance. Attendees consistently walk away with best practices for a well-designed, multi-faceted approach to
GTN management for enhanced visibility, profitability and control.

CPE Credits!
Pending Approval

Choose from multiple workshops, learning labs and tracks of content to tailor your learning to your business needs.

This In-Depth Event Arms You
with Strategies to:

  • Accurately capture, monitor and report GTN data
  • Forecast and plan for GTN liabilities
  • Estimate product returns with little to no historical data
  • Manage GTN for return accruals, new product launches and
    patent expiries/discontinuation/recalls
  • Report and understand indirect/non-contracted sales
  • Account for coupon, copay and voucher programs
  • Anticipate and substantiate shifts in chargebacks
  • Assess the financial impact of Healthcare reform


Excellent opportunity to network with peers and opportunity to meet software vendors and solution providers.

Chief Financial Officer, Kowa Pharmaceuticals

The CBI Gross-to-Net Conference offers a broad range of experiences and knowledge to help navigate this
complex and unclear critical business area.

Manager, Chargebacks, Fresenius Kabi

A premier event for finance professionals in the healthcare industry… Would be difficult to surpass.

Worldwide Biopharma Business Controller, Pfizer Inc